2026 年 3 月 3 日 星期二 每日大市点评 昨日港股下跌。恒生指数及国企指数分别收报 26,059.85 点及 8,701.91 点，下跌 2.1%及 1.8%。港股成交合共 3,577 港 元，较上周五的 2,884 亿港元，下跌 24.0%，或反映投资者轮动交易情况。分类指数方面，能源、原材料、公用事业业指 数分别上升 4.0%、3.1%、0.1%；医疗保健、金融、非必需性消费则分别下跌 3.4%、3.3%、3.1%。蓝筹个股方面，信义玻 璃(868 HK)及中国宏桥(1378 HK)领涨，分别上升 12.4%及 7.2%；京东健康(6618 HK)及汇丰控股(5 HK)领跌，皆分别下跌 5.2%。 近日美国及以色列攻击伊朗，这无疑加深地缘政治危机，以及影响石油及天然气等传统能源供应。WTI 原油价格上涨至 70 美元近月高水平，虽然如此，仍远低于 2022 年俄乌军事冲突爆发时候的 100 至 115 美元水平。黄金价格则上升至今年初 的 5,300 美元高水平。在此次战争情况下，相关港股板块表现出传统投资逻辑。"三桶油"上升 2.6%-5.6%，金矿股例如 招金矿业(1818 HK)上升 6. ...

Core Insights - The study published in the International Journal of Molecular Sciences reveals that the GLP-1 receptor agonist, polyethylene glycol-liraglutide (brand name: Fulaimei), accelerates diabetic wound healing through a dual mechanism: systemic anti-inflammatory regulation and restoration of endothelial progenitor cell (EPC) function [1][2]. Group 1: Research Findings - Diabetes is a leading cause of death and disability globally, with vascular complications such as chronic wound healing delays posing significant clinical challenges [1]. - The research utilized a mouse model to compare wound healing in diabetic mice treated with Fulaimei, untreated diabetic mice, and normal mice, demonstrating that Fulaimei improves metabolic disorders, accelerates wound healing, regulates systemic inflammation, and restores EPC function [2]. - Previous in vitro studies indicated that liraglutide can improve EPC damage and mitochondrial dysfunction via the SIRT3/Foxo3 signaling pathway [2]. Group 2: Clinical Implications - The study provides theoretical support for the use of Fulaimei in treating diabetic vascular complications and offers a new strategy for chronic wound treatment in diabetes [2]. - The findings expand the clinical application prospects of GLP-1 receptor agonists, suggesting potential use in other diseases related to mitochondrial dysfunction [2]. - Future research will further explore the efficacy and molecular regulatory networks of Fulaimei in human subjects [2].